PTIX vs. GHSI, RDHL, IMNN, PHXM, CDIO, TNXP, ERNA, KA, OBSV, and WENA
Should you be buying Protagenic Therapeutics stock or one of its competitors? The main competitors of Protagenic Therapeutics include Guardion Health Sciences (GHSI), RedHill Biopharma (RDHL), Imunon (IMNN), PHAXIAM Therapeutics (PHXM), Cardio Diagnostics (CDIO), Tonix Pharmaceuticals (TNXP), Eterna Therapeutics (ERNA), Kineta (KA), ObsEva (OBSV), and ANEW Medical (WENA). These companies are all part of the "pharmaceutical products" industry.
Guardion Health Sciences (NASDAQ:GHSI) and Protagenic Therapeutics (NASDAQ:PTIX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, community ranking, media sentiment and valuation.
In the previous week, Guardion Health Sciences had 1 more articles in the media than Protagenic Therapeutics. MarketBeat recorded 2 mentions for Guardion Health Sciences and 1 mentions for Protagenic Therapeutics. Guardion Health Sciences' average media sentiment score of 1.87 beat Protagenic Therapeutics' score of 0.70 indicating that Protagenic Therapeutics is being referred to more favorably in the news media.
20.2% of Guardion Health Sciences shares are owned by institutional investors. Comparatively, 8.0% of Protagenic Therapeutics shares are owned by institutional investors. 1.3% of Guardion Health Sciences shares are owned by company insiders. Comparatively, 37.0% of Protagenic Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Protagenic Therapeutics has a net margin of 0.00% compared to Protagenic Therapeutics' net margin of -16.69%. Protagenic Therapeutics' return on equity of -77.29% beat Guardion Health Sciences' return on equity.
Guardion Health Sciences has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500. Comparatively, Protagenic Therapeutics has a beta of 0.27, suggesting that its stock price is 73% less volatile than the S&P 500.
Guardion Health Sciences has higher revenue and earnings than Protagenic Therapeutics. Guardion Health Sciences is trading at a lower price-to-earnings ratio than Protagenic Therapeutics, indicating that it is currently the more affordable of the two stocks.
Guardion Health Sciences received 62 more outperform votes than Protagenic Therapeutics when rated by MarketBeat users.
Summary
Guardion Health Sciences beats Protagenic Therapeutics on 8 of the 13 factors compared between the two stocks.
Get Protagenic Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PTIX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PTIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Protagenic Therapeutics Competitors List
Related Companies and Tools
